A recent study [62] demonstrated that EZH2 inhibition is able to reverse the tumor phenotype of embryonic rhabdomyosarcoma RD cell lines and in alveolar rhabdomyosarcoma cell lines [63], even in the presence of proliferative stimuli, such as the addition of serum to growth conditions. This evidence concerns the gene EZH2 and neoplasm.